ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Neuropharmacology
The Development and verification of clinical medication pathway for tic disorder in west China
Provisionally accepted
- 1Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China
- 2Sichuan University West China Second University Hospital, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: The purpose of this study was to construct a clinical medication pathway for children with tic disorder (TD) and provide a reference for rational drug use for children with TD. Methods: A literature review was performed to develop an initial clinical medication pathway. Next, a two-round Delphi survey was implemented. A prospective cohort study was carried out to evaluate effectiveness of the constructed clinical medication pathway. Results: In total, 26 experts (80.8% doctors, 11.5% pharmacists, 7.7% nurses) from Level III medical institutions from west China were included in the Delphi survey. After two rounds of expert consultation, a clinical medication pathway was constructed, comprising 41 items across eight dimensions, these dimensions include participants of the clinical medication management, TD assessment, comorbidity assessment, treatment goals and plans, medication treatment for tics, medication treatment for comorbid ADHD, recurrence and referral management and medication adherence management. A total of 100 TD patients were consecutively recruited from the outpatient clinic, with 50 cases (8.01±2.49, 35 male) assigned to the clinical medication pathway group and 50 cases (8.25±2.49, 35 male) to the routine treatment group. After 12 weeks of treatment, the clinical medication pathway group showed higher scores in efficacy rate (82% vs 58%, p=0.009), YGTSS score (23.86±6.53 vs 30.68±7.26, p<0.000), medication adherence (7.47±0.746 vs 4.32±1.391, p<0.000) and in the caregivers' ratings of service quality (4.46±0.706 vs 4.10±0.839, p=0.022), service attitude(4.28±0.701 vs 3.80±0.881, p=0.003), service efficiency(4.20±0.990 vs 3.78±1.016, p=0.039), professional level(4.36±0.631 vs 3.94±0.956, p=0.011), and visit satisfaction (4.44±0.675 vs 3.94±0.956, p=0.011) compared to the routine treatment group. Conclusion: This study actively explored clinical medication pathways for children with TD in China and provided a standardized and highly operable medication pathway for reference in clinical practice. This pathway is expected to be widely used in treatment for children with TD. We suggest that further research should update and improve the clinical medication pathway using the latest evidence.
Keywords: clinical medication pathway, tic disorder, Medication compliance, Management strategy, Evidence-Based Medicine
Received: 09 Aug 2025; Accepted: 24 Oct 2025.
Copyright: © 2025 Yang, Li and ZHANG. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chunsong Yang, yangchunsong_123@126.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.